Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Price:
150.24 USD
0.56%
Market Closed
Updated:
May 21, 2024
Alnylam Pharmaceuticals Inc
Research & Development
|
Alnylam Pharmaceuticals Inc
Research & Development Peer Comparison
Comparables:
ABBV
GILD
AMGN
VRTX
REGN
Competitive Research & Development Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
Research & Development
-$1B
|
CAGR 3-Years
-16%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
-11%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Research & Development
-$7.3B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
-9%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Research & Development
-$6B
|
CAGR 3-Years
18%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-10%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Research & Development
-$5B
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
-2%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Research & Development
-$3.5B
|
CAGR 3-Years
-24%
|
CAGR 5-Years
-19%
|
CAGR 10-Years
-14%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Research & Development
-$4.6B
|
CAGR 3-Years
-17%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
-17%
|
See Also
What is Alnylam Pharmaceuticals Inc's Research & Development?
Research & Development
-1B
USD
-1B
USD
Based on the financial report for Mar 31, 2024, Alnylam Pharmaceuticals Inc's Research & Development amounts to -1B USD.
What is Alnylam Pharmaceuticals Inc's Research & Development growth rate?
Research & Development CAGR 10Y
-11%
-11%
Over the last year, the Research & Development growth was -10%. The average annual Research & Development growth rates for Alnylam Pharmaceuticals Inc have been -16% over the past three years , -14% over the past five years , and -11% over the past ten years .
You don't have any saved screeners yet
